Risk adjusted net present value: What is the current valuation of Lumos Pharma’s Oratrope?
Oratrope is a small molecule commercialized by Lumos Pharma, with a leading Phase II program in Growth Hormone Deficiency.
Oratrope is a small molecule commercialized by Lumos Pharma, with a leading Phase II program in Growth Hormone Deficiency.
What's Your Reaction?
